Trial Outcomes & Findings for Helium-oxygen Gas Mixtures Delivered by a High Flow Nasal Cannula in Bronchiolitis (NCT NCT02373683)

NCT ID: NCT02373683

Last Updated: 2022-03-02

Results Overview

Change in the respiratory assessment score from baseline (within 15 minutes of extubation) to 48 hours after extubation. The score ranges from 0 to 12, with higher scores indicating worsening respiratory distress.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

48 hours

Results posted on

2022-03-02

Participant Flow

Participant milestones

Participant milestones
Measure
Vapotherm-Heliox
Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system. Vapotherm-Heliox: Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
Standard Care
Care dictated by clinical team.
Overall Study
STARTED
6
4
Overall Study
COMPLETED
6
4
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Data was not collected or analyzed.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Vapotherm-Heliox
n=6 Participants
Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system. Vapotherm-Heliox: Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
Standard Care
n=4 Participants
Care dictated by clinical team.
Total
n=10 Participants
Total of all reporting groups
Sex/Gender, Customized
0 Participants
Data was not collected or analyzed
0 Participants
Data was not collected or analyzed
0 Participants
Data was not collected or analyzed
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Primary diagnosis
0 Participants
Data was not collected or analyzed
0 Participants
Data was not collected or analyzed
0 Participants
Data was not collected or analyzed

PRIMARY outcome

Timeframe: 48 hours

Population: Study was terminated early. Data were not collected and results were not analyzed.

Change in the respiratory assessment score from baseline (within 15 minutes of extubation) to 48 hours after extubation. The score ranges from 0 to 12, with higher scores indicating worsening respiratory distress.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: During hospitalization, typically 4 days to 2 weeks

Population: Study was terminated early. Data were not collected and results were not analyzed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: During hospitalization, typically 4 days to 2 weeks

Population: Study was terminated early. Data were not collected and results were not analyzed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: During hospitalization, typically 4 days to 2 weeks

Population: Study was terminated early. Data were not collected and results were not analyzed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: During hospitalization, typically 4 days to 2 weeks

Population: Study was terminated early. Data were not collected and results were not analyzed.

Outcome measures

Outcome data not reported

Adverse Events

Vapotherm-Heliox

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Standard Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Katherine Slain

Case Western Reserve University

Phone: 12168443310

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place